In conclusion, we provided evidence that wild type survivin is an attractive target for the immunotherapy against oral cancer as well as survivin-2B, and survivin targeting immunotherapy using survivin-2B80-88 and C58 peptide cocktail should be suitable for HLA-A24+ cancer patients. This evidence concerns the gene BIRC5 and cancer.